CFM
SLRN

Catalyst Funds Management’s ACELYRIN SLRN Stock Holding History

Catalyst Funds Management’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,000
Closed -$4.41K – 1578
2024
Q2 		$4.41K Buy
+1,000
New +$4.69K ﹤0.01% 1075

Other funds holding SLRN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Catalyst Funds Management's SLRN Position: Q3 2024 in Review

Catalyst Funds Management sold out of ACELYRIN (SLRN) in Q3 2024, closing a stake of 1,000 shares — an estimated $4.41K sold.

Catalyst Funds Management first reported a position in SLRN in Q2 2024 and held it in 1 quarter. The position peaked at $4.41K in Q2 2024. 122 funds tracked by Wall St. Rank hold SLRN as of Q3 2024.

  • Catalyst Funds Management reported no remaining ACELYRIN position as of Q3 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 1,000 ACELYRIN shares in Q3 2024, an estimated $4.41K.
  • Catalyst Funds Management first reported a position in ACELYRIN in Q2 2024 and held it in 1 quarter.
  • Catalyst Funds Management's ACELYRIN position peaked at $4.41K in Q2 2024.
  • 122 funds tracked by Wall St. Rank held ACELYRIN as of Q3 2024.

Based on Catalyst Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.